Novo Nordisk swells alliance with AI firm Valo Health
Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
Galapagos unveils plan to split, hiving off its drugs unit
Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.
11 blockbuster drugs to look out for in 2025
Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
Aviceda raises $207.5m for eye drug, and other financings
Our round-up of recent biotech financings includes a big round for Aviceda, with Orbis, Alebund, XyloCor, and PrimeGene also raising additional cash.
J&J says Rybrevant combo has survival edge over Tagrisso
Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
Welcome to the Bacteriophage Therapy Summit!
Combating Antibiotic Resistance with Effective & Sustainable Phage-Based Therapies
Biotech Showcase marking 17 years of innovation and opportun...
Biotech Showcase is a cornerstone of the life science industry, with a 17-year history of connecting private and micro- to mid-cap biotech companies with top-tier investors and biopharmaceu